白蛋白结合型紫杉醇联合奈达铂化疗对复发转移性宫颈癌的效果及血清CYFRA21-1、VEGF-C水平的影响

Effect of combined albumin-bound paclitaxel and nedaplatin on recurrent and metastatic cervical cancer and serum CYFRA21-1 and VEGF-C levels

目的了解白蛋白结合型紫杉醇联合奈达铂化疗对复发转移性宫颈癌的效果及血清细胞角蛋白19片段抗原21-1(CYFRA21-1)、血管内皮生长因子C(VEGF-C)水平的影响。方法70例复发转移性宫颈癌患者分别采用溶剂型紫杉醇联合奈达铂化疗(对照组)或白蛋白结合型紫杉醇联合奈达铂化疗(研究组),比较两组疗效、不良反应及血清CYFRA21-1、VEGF-C水平。结果研究组疗效优于对照组(P<0.05),血清CYFRA21-1、VEGF-C水平及不良反应低于对照组(P<0.01或0.05)。结论白蛋白结合型紫杉醇联合奈达铂治疗复发转移性宫颈癌患者疗效确切、安全性较高,可降低患者血清CYFRA21-1和VEGF-C水平。

Objective To study the effect of combined albumin-bound paclitaxel(ABP)and nedaplatin on recurrent and metastatic cervical cancer(RMCC)and serum CYFRA21-1 and VEGF-C levels.Methods Seventy patients with RMCC were treated with solvent-based paclitaxel+nedaplatin(control group)or ABP+nedaplatin(study group).Clinical efficacy,adverse reactions,and serum CYFRA21-1 and VEGF-C levels were compared between two groups.Results Compared with control group,clinical efficacy was higher(P<0.05),while serum CYFRA21-1 and VEGF-C levels and adverse reactions were lower(P<0.01 or 0.05)in study group.Conclusion Combined use of ABP and nedaplatin is effective and safe for RMCC,and reduces serum CYFRA21-1 and VEGF-C contents.